Improvements in health-related quality of life (HRQoL) in the SUNMO study: Subcutaneous (SC) mosunetuzumab plus polatuzumab vedotin (Mosun-Pola) vs rituximab, gemcitabine and oxaliplatin (R-GemOx) in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after at least one prior therapy
Won-Seog Kim(Samsung Medical Center), Mark Fesler(St. Luke's Hospital), Huilai Zhang(Shanxi Medical University), Hideki Goto(Hokkaido University Hospital), Jason R. Westin(The University of Texas MD Anderson Cancer Center), Boone Goodgame(The University of Texas at Austin), Dai Maruyama(National Cancer Center), Eduardo Magalhães Rego(Universidade de São Paulo), Zhiming Li(Lanzhou University of Technology), Connie Lee Batlevi(Memorial Sloan Kettering Cancer Center), Huangming Hong(Sun Yat-sen University), Michael C. Wei(The Royal Melbourne Hospital), Wahib S. Ead(Acentech (United States)), Shen Yin, Martin Janousek(Roche (Switzerland)), Song Pham(Roche (Canada))
Cited by 0
Related Papers
tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c
|Genes & Development|2000|1.3k
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782
Light‐Triggered Theranostics Based on Photosensitizer‐Conjugated Carbon Dots for Simultaneous Enhanced‐Fluorescence Imaging and Photodynamic Therapy
|Advanced Materials|2012|696